TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3781678

Group type: EXPERIMENTAL
Intervention: Standard dose: CHL 25 mg and MET 200 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lower dose: CHL 12.5 mg and MET 100 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Higher dose (standard dose) vs Lower dose
Number of subjects: 73
Study: 27749603

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) with Raltegravir (400 mg twice daily, Arm1)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily) with Tenofovir/Emtricitabine (245/200 mg once daily, Arm2)
Number of subjects: 343
Study: 26474979

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including web-enabled device, training sessions, coaching, clinician education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study: 23414551

Group type: EXPERIMENTAL
Intervention: Diet containing monounsaturated fat (MUFA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diet containing butter fat (SFA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Supplementation with long-chain n-3 fatty acids
Number of subjects: 34
Study: 20096545

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (staest) spread (2 g/day) for four weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Plant sterol ester (steest) spread (2 g/day) for four weeks
Number of subjects: 22
Study: 19900235

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 51
Study: 17326149

Group type: EXPERIMENTAL
Intervention: Isoleucine infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 16
Study: 15358024

Group type: EXPERIMENTAL
Intervention: Diet/exercise intervention
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 353
Study: 11485010

Group type: EXPERIMENTAL
Intervention: Continuous magnetic field exposure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent magnetic field exposure
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (no exposure)
Number of subjects: 24
Study: 10984298

Group type: EXPERIMENTAL
Intervention: Somatropin treatment (rhGH, 12 microg/kg/day) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8181259

Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: High saturated fat baseline diet
Number of subjects: 25
Study: 3310721

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 0.005 mg/kg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 92
Study: 31852410

Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolysis (recombinant tissue plasminogen activator, 0.5 mg/ml, maximum dose limit 22.5 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intraarterial placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolysis
Number of subjects: 200
Study: 31969360

Group type: EXPERIMENTAL
Intervention: One-stage revision surgery
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Two-stage revision surgery
Number of subjects: 57
Study: 30481596

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone prophylaxis (group B)
Number of subjects: 228
Study: 28775279

Group type: EXPERIMENTAL
Intervention: Leaching fraction of 0.29
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in irrigation water salinity (ECiw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in leaching fraction (LF)
Number of subjects: 0
Study: 25294647

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells (BMMCs)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMCs)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study: 22884376

Group type: EXPERIMENTAL
Intervention: Permanent running lights mounted to bicycles
Number of subjects: 3845

Group type: COMPARATOR
Intervention: Control group without bicycle running lights
Number of subjects: 3845
Study: 20974293

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 240
Study: 20032546

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a 180 microg/week plus ADV 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2a monotherapy
Number of subjects: 60
Study: 18028568

Group type: EXPERIMENTAL
Intervention: Feedback and education intervention at site 1
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group at site 2 (no feedback or education)
Number of subjects: 59
Study: 14973216

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg per day)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg per day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Reference group (27 untreated patients)
Number of subjects: 149
Study: 11281392

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (Pnc PS)
Number of subjects: 44
Study: 9677439

Group type: EXPERIMENTAL
Intervention: High dose IL-2/IFN-alpha combination therapy (protocol 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low dose, long-term continuous IFN-alpha/IL-2 administration (protocol 2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low dose IFN-alpha and 13-cis-retinoic acid therapy in repetitive weekly cycles (protocol 3)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 67
Study: 7988246

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant intrapleural bacillus Calmette‐Guérin (BCG)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Saline solution placebo control
Number of subjects: 473
Study: 2735177

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg ATR
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg DTC
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 44
Study: 29567335

Group type: EXPERIMENTAL
Intervention: Family nursing therapeutic conversations (FNTC) as a supplement to usual care
Number of subjects: 347

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 347
Study: 28244559

Group type: EXPERIMENTAL
Intervention: LOW+ resistance exercise (1x60 repetitions at 20%1RM followed by 1x10-20 repetitions at 40%1RM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: HIGH-resistance (2x10-15 repetitions at 80%1RM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: LOW-resistance (1x80-100 repetitions at 20%1RM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Mixed-low LOW+ resistance
Number of subjects: 47
Study: 26664396

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) plus Risperidone (6 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus Risperidone (6 mg/day)
Number of subjects: 40
Study: 23144046

Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion during the first 48 hours of hospitalization for AMI
Number of subjects: 578
Study: 21755218

Group type: EXPERIMENTAL
Intervention: Educational video for promoting attachment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 24
Study: 19663190

Group type: EXPERIMENTAL
Intervention: Combined basic treatment with methotrexate (7.5 mg/week) and plaquenil (0.2 mg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 142
Study: 16675725

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 15239097

Group type: EXPERIMENTAL
Intervention: Clevudine 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clevudine 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clevudine 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clevudine 200 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clevudine (all doses)
Number of subjects: 32
Study: 11535908

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound during initial ED resuscitation
Number of subjects: 208

Group type: COMPARATOR
Intervention: No ultrasound (control)
Number of subjects: 208
Study: 9205761

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg and Cimetidine 800 mg
Number of subjects: 30
Study: 1770193

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN) via needle catheter jejunostomy (NCJ) within 12 hours post-laparotomy.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) after postoperative day 5.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN) via NCJ during the same postoperative period.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN).
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN).
Number of subjects: 63
Study: 7066138

Group type: EXPERIMENTAL
Intervention: Extradural pethidine 25 mg with adrenaline 25 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extradural pethidine 25 mg without adrenaline
Number of subjects: 20
Study: 30462220

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Study drug interrupted ≤3 days
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Study drug interrupted >3 days
Number of subjects: 1145
Study: 29051133

Group type: EXPERIMENTAL
Intervention: Web- and app-based health promotion tool (SoSu-life)
Number of subjects: 355
Study: 27068695

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg oral doses)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 22889073

Group type: EXPERIMENTAL
Intervention: Exposure to failure information in individuals with obsessive passion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to success or failure information in individuals with harmonious passion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Framing of performance task with important negative consequences for the self after failure information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Framing of performance task as inconsequential after failure information
Number of subjects: 0
Study: 21069585

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion-focused therapy (T-SEFT)
Number of subjects: 127
Study: 19814748

Group type: EXPERIMENTAL
Intervention: Flexometallic tracheal tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: ILMA tube
Number of subjects: 60
Study: 16622262

Group type: EXPERIMENTAL
Intervention: Dermoscopy evaluation arm
Number of subjects: 73

Group type: COMPARATOR
Intervention: Naked-eye evaluation arm
Number of subjects: 73
Study: 15596679

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg bid)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11269767

Group type: EXPERIMENTAL
Intervention: Topical allergen challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with nasal allergy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (not specified)
Number of subjects: 0
Study: 9821833

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study: 8310985

Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapeseed oil with 1 g squalene for 9 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (rapeseed oil without squalene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 g squalene/d for 6 weeks
Number of subjects: 0
Study: 3396238

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (Mg) therapy for 48 hours
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 270
Study: 27297443

Group type: EXPERIMENTAL
Intervention: Small-sided ball game group (SSG)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Circuit strength training group (CST)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 295
Study: 26095455

Group type: EXPERIMENTAL
Intervention: Tapentadol PR 50 mg (titrated to maximum 250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone/naloxone PR 10 mg/5 mg (titrated to maximum 40 mg/20 mg plus oxycodone PR 10 mg)
Number of subjects: 0
Study: 25808944

Group type: EXPERIMENTAL
Intervention: Capecitabine (Cape)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5'‐deoxy‐5‐fluorocytidine (DFCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5'‐deoxy‐5‐fluorouridine (DFUR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 0
Study: 23707930

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21940331

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of metoclopramide (15 minutes before swallowing CE)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (no metoclopramide)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of metoclopramide
Number of subjects: 177
Study: 18332401

Group type: EXPERIMENTAL
Intervention: Psyllium supplementation at 7 or 14 g/d for 3 months
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 158
Study: 16520350

Group type: EXPERIMENTAL
Intervention: Folinic acid (50 mg i.v. once weekly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Folinic acid (500 microg/min intra-arterially)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 34
Study: 14605047

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 800 microg/d for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-dose ICS (group B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose FP (group A)
Number of subjects: 10
Study: 10883990

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25 % bupivacaine instilled into the gallbladder bed and Calot's triangle area
Number of subjects: 75

Group type: COMPARATOR
Intervention: No bupivacaine instillation
Number of subjects: 75
Study: 8883017

Group type: EXPERIMENTAL
Intervention: A1(OH)3 1 tablet 3 times per day (about 302 mg/day of elemental A1) for 3 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no A1 exposure)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: A1(OH)3
Number of subjects: 55
Study: 8140182

Group type: EXPERIMENTAL
Intervention: Fluvoxamine and exposure therapy (group Fe)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure therapy with placebo (group Pe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiexposure therapy with fluvoxamine (group F)
Number of subjects: 60
Study: 3524320

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 29680962

Group type: EXPERIMENTAL
Intervention: Positive Cognitive Bias Modification training for Interpretation (CBM-I)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Neutral control-CMB-I-training
Number of subjects: 69
Study: 26485620

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (5 annual scans)
Number of subjects: 4104
Study: 23249766

Group type: EXPERIMENTAL
Intervention: Enriched milk group (EMG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo milk group (PMG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 101
Study: 23106107

Group type: EXPERIMENTAL
Intervention: Secukinumab 3 × 150 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Secukinumab 3 × 75 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 21967800

Group type: EXPERIMENTAL
Intervention: SMATH® system (automatic thermomechanic massage)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham therapy (medical device without active principles)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SMATH® system
Number of subjects: 72
Study: 18552606

Group type: EXPERIMENTAL
Intervention: Acupuncture (needle or electroacupuncture)
Number of subjects: 1456
Study: 16371228

Group type: EXPERIMENTAL
Intervention: Active management of the third stage of labor with 600 mcg of oral misoprostol
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Current government guidelines for the prevention of PPH (control group)
Number of subjects: 1200
Study: 14616378

Group type: EXPERIMENTAL
Intervention: 5% alpha-lipoic acid cream
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 33
Study: 10781516

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 9203484

Group type: EXPERIMENTAL
Intervention: Physiotherapy and biofeedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 40
Study: 1557594

Group type: EXPERIMENTAL
Intervention: Training with sleep markers (A, B, C) and feedback
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (no feedback, no markers)
Number of subjects: 10
Study: 6372422

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study: 31321071

Group type: EXPERIMENTAL
Intervention: 20 mg/day fluoxetine for 60 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo for 60 days
Number of subjects: 20
Study: 29604295

Group type: EXPERIMENTAL
Intervention: Δ9‐THC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Δ9‐THC + CBD
Number of subjects: 21

Group type: COMPARATOR
Intervention: CBD
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CP‐55940
Number of subjects: 21

Group type: COMPARATOR
Intervention: CP‐55940 + AM‐251
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 21
Study: 27368881

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily; 3 weeks on/1 week off) with fulvestrant (500 mg intramuscular injection)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo with fulvestrant (500 mg intramuscular injection)
Number of subjects: 521
Study: 25191661

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg oral midazolam premedication
Number of subjects: 62

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 62
Study: 23456359

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 278
Study: 20082603

Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18786287

Group type: EXPERIMENTAL
Intervention: Amniocentesis-based management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 40
Study: 15960574

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated estrogen
Number of subjects: 17

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 17
Study: 12024136

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (imager view)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard colonoscopy (without imager view)
Number of subjects: 122
Study: 12198787

Group type: EXPERIMENTAL
Intervention: Implicit test with weakly related word pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit test with strongly related word pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit test with weakly related word pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit test with strongly related word pairs
Number of subjects: 0
Study: 7669311

Group type: EXPERIMENTAL
Intervention: Guanfacine 1 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2279253

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg t.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 876918

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 110

Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Debrisoquine
Number of subjects: 110
Study: 31174452

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Radical cystectomy (RC) alone
Number of subjects: 944
Study: 27552722

Group type: EXPERIMENTAL
Intervention: Canine-to-canine retainer bonded to the canines
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bonded twistflex retainer 3-3, bonded to each tooth
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both retainers
Number of subjects: 64
Study: 25371450

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 925
Study: 23836811

Group type: EXPERIMENTAL
Intervention: Adjustment group (6 group treatment sessions)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care (no psychological interventions)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Adjustment group
Number of subjects: 221
Study: 21269526

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 in Ringer's acetate
Number of subjects: 800

Group type: COMPARATOR
Intervention: Ringer's acetate alone
Number of subjects: 800
Study: 19638505

Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24